The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient-Reference-Cited by-同舟云学术

The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient

Published:2015-12-09 Issue:9 Volume:18 Page:915-924
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

Mlak R.^ORCID,Krawczyk P.,Ciesielka M.,Kozioł P.,Homa I.,Powrózek T.,Prendecka M.,Milanowski J.,Małecka-Massalska T.

Funder

Medical University of Lublin

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-015-1461-1.pdf

Reference26 articles.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. CA Cancer J Clin. 2013;63:11–30.

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer version 1.2015 (2015) http://www.nccn.org . Accessed 25 June 2015.

3. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, et al. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014;15:173–81.

4. Simon GR, Somaiah N. A tabulated summary of targeted and biologic therapies for non-small-cell lung cancer. Clin Lung Cancer. 2014;15:21–51.

5. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C8ORF59 regulates ribosome biogenesis to affect progression in lung adenocarcinoma;2024-04-26

2. Cellular resistance mechanisms in cancer and the new approaches to overcome resistance mechanisms chemotherapy;Saudi Medical Journal;2023-04

3. Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors;Frontiers in Pharmacology;2022-01-10

4. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer;Neoplasia;2021-07

5. A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non‐small cell lung cancer;British Journal of Pharmacology;2021-02-27